Full-Time

Oncology Product Manager

Deadline 10/1/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

No salary listed

Île-de-France, France

In Person

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Market Research
Data Analysis

Get referred to Merck

See people who can refer or advise you

Requirements
  • A higher-education Bac+5 qualification with dual scientific and business-school training is required.
  • At least 3–4 years of experience in the pharmaceutical industry across product management, market research, or field roles is required.
  • Experience in the relevant therapeutic area is preferred.
  • The role requires customer orientation and the ability to work collaboratively.
  • The role requires excellent written and oral communication and interpersonal skills.
  • The role requires ethical leadership, integrity, courage, creativity, rigor, autonomy, organization, planning, teamwork, and flexibility.
  • The role requires the ability to persuade and challenge the status quo.
  • The role requires curiosity, an innovative mindset, and initiative.
  • The role requires strong analytical skills for proposing relevant strategic and action plans.
  • The role requires detailed knowledge of the therapeutic area and its internal and external ecosystem.
  • The role requires fluent English at B2 level.
Responsibilities
  • Own the marketing plan for assigned indications and products or product lines.
  • Execute the identified customer strategy to achieve established objectives.
  • Develop communications and implement innovative, differentiated initiatives.
  • Ensure consistency between product or product-line strategy and activities in collaboration with the dedicated Core Team and Global teams.
  • Develop expertise in the assigned market and its evolution.
  • Identify research needs and conduct market analyses in close collaboration with the Market Research team.
  • Own the market research plan.
  • Continuously develop in-depth knowledge of customer types through close collaboration with field teams.
  • Build recognition among scientific experts and key stakeholders in the care pathway.
  • Define and execute customer segmentation aligned with product or product-line strategy.
  • Identify customer needs and develop suitable projects.
  • Develop the marketing plan in line with global strategy and obtain validation from management.
  • Manage the Core Team and coordinate internal stakeholders needed to define strategy and deliver customer-focused operations.
  • Develop or supervise the development of promotional and environmental materials with the Junior Product Manager, in accordance with strategy, regulations, and internal procedures.
  • Ensure that field teams adopt and understand campaigns.
  • Qualitatively analyze campaign impact through joint field days with representatives and expert committees.
  • Develop an omnichannel communication strategy for the market with digital and data teams.
  • Monitor customer understanding, satisfaction, and proper use of the product or product line through appropriate feedback.
  • Define, collect, and analyze performance indicators to measure the impact of campaigns and services, using digital and data where relevant.
  • Participate in international meetings and ensure that France’s interests and needs are understood and integrated at Global level.
  • Define and propose innovative projects aligned with strategy and customer needs in collaboration with internal experts.
  • Participate in cross-functional projects requiring marketing expertise.
  • Track product or product-line performance using available tools, including Navboard and market research, and propose an appropriate action plan.
  • Prepare sales forecasts for the product or product line.
  • Own product budget monitoring and make adjustments when necessary.
  • Perform the role in compliance with French regulations and applicable internal processes.
Desired Qualifications
  • Experience in the relevant therapeutic area is preferred.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 melanoma data validated Merck's next-generation cancer franchise beyond Keytruda.
  • July 2026 Lipfendra approval opens a new cardiovascular growth market before Keytruda erosion.
  • February 2026 oncology reorganization concentrates resources ahead of patent expiry and late-stage launches.

What critics are saying

  • Keytruda loses U.S. compound patent protection in December 2028, pressuring oncology revenue.
  • Summit and Akeso's ivonescimab beat Keytruda in China lung cancer data in 2026.
  • Merck's 2025 $3 billion cost-cutting plan includes 6,000 layoffs, signaling margin strain.

What makes Merck unique

  • Keytruda remains Merck's oncology engine; July 2026 approvals expanded perioperative bladder and kidney use.
  • August 2026 Moderna partnership produced first positive Phase 3 individualized mRNA cancer vaccine results.
  • Lipfendra's July 2026 FDA approval created Merck's first oral PCSK9 inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Sep 8th, 2026
Merck cuts 54 jobs in New Jersey as part of $3B cost-reduction plan

Merck & Co. will lay off 54 workers at its Rahway, New Jersey facility in two phases on 11 December 2026 and 4 January 2027, according to a September filing with the state Department of Labor. The cuts are part of a company-wide initiative announced in 2025 to reduce costs by $3 billion by 2027. The pharmaceutical company said savings from the cost-cutting measures would support new products. This follows a previous notice filed in June covering 88 employees, with layoffs scheduled for 4 September. The company has not disclosed the total number of job cuts planned under the initiative.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Latest Nigerian News
Sep 5th, 2026
Merck, Cond Nast and Cargill all recently appointed female cfos.

Merck, Cond Nast and Cargill all recently appointed female cfos. Published by Forbes on Fri, 02 Apr 2021 March was a great month for women in finance. Last week, pharmaceutical giant Merck tapped Caroline Litchfield as its new CFO, while media company Cond Nast named Jackie Marks to lead its finance function. Earlier in the month, food corporation Cargill announced Jamie Miller as finance chief.

BioSpace
Sep 3rd, 2026
Summit, Akeso's ivonescimab bests Merck's Keytruda in China trial - again.

Summit, Akeso's ivonescimab bests Merck's Keytruda in China trial - again. September 3, 2026 | New Phase 3 data show that Summit Therapeutics and Akeso's PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck's Keytruda but the results will need to be replicated in non-Chinese patients. Summit Therapeutics and Akeso's upcoming PD-1/VEGF bispecific antibody has officially bested Merck's mega-blockbuster Keytruda on both overall survival and progression free survival in a type of non-small cell lung cancer. The latest results for the partners could establish a new paradigm in NSCLC treatment where ivonescimab becomes the regimen of choice among oncologists, analysts said. But the new data from the Phase 3 HARMONi-2 trial comes from Chinese clinical trials. Summit still has to verify the results in Western patients to get the FDA on board for a clean regulatory review. Akeso on Thursday announced interim results from the Phase 3 HARMONi-2 trial, which compared ivonescimab against Keytruda in patients with first-line NSCLC with tumors that express PD-L1. The drug is already approved in China for this type of cancer, as well as two others, but has yet to be cleared in the U.S. for any indication. Ivonescimab met the key secondary goal of improving overall survival (OS). The companies previously announced the achievement of the main progression-free survival (PFS) endpoint in May 2024, earning the antibody the nickname Keytruda killer. The therapy achieved PFS of 11.14 months as compared to Keytruda's 5.82 months. Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement - but the early analysis delivered disappointment for the company and shareholders. May 4, 2026 "Akeso's HARMONi-2 study has now demonstrated both PFS and OS superiority versus Keytruda in China, raising the possibility that future NSCLC regimens may increasingly be judged against ivonescimab rather than Keytruda," Jefferies wrote in a Thursday morning note. "While investors can reasonably debate whether China data will fully translate globally," the analysts continued, "this latest OS readout strengthens the case for ivonescimab as a potential next-generation immunotherapy backbone in NSCLC." Summit's shares rose over 7% to $15.65 in early morning trading Thursday. Akeso did not reveal detailed data on the OS endpoint but promised to do so at a future medical meeting and in a peer-reviewed journal. In the meantime, Summit is working on confirming these achievements in trials conducted elsewhere. A key test will be the outcome of the global Phase 3 HARMONi-3 trial, which is testing ivonescimab with chemotherapy against Keytruda in patients with first-line metastatic NSCLC. After the drug was approved for this indication in China, the regulator there released additional data on the label that suggested a degradation of the PFS benefit. Analysts raised concerns that the HARMONi-3 trial may not show a sufficient benefit to warrant an accelerated approval from the FDA. Summit is expected to reveal data from HARMONi-3 sometime this half. In May, an early interim analysis of PFS from HARMONI-3 failed to reach statistical significance, postponing Summit's plans for a regulatory filing in this indication. Summit is, however, currently awaiting a November FDA decision for the therapy in NSCLC with mutations in the gene for epidermal growth factor receptor (EGFR). Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso's HARMONi-6 trial left them wanting. May 31, 2026

DIGITIMES
Sep 3rd, 2026
Electroninks, Merck, Qualipoly build advanced packaging ecosystem.

Electroninks, Merck, Qualipoly build advanced packaging ecosystem. Sep 4, 2026, 07:53 0 Credit: DIGITIMES Electroninks, a global provider of metal-composite conductive inks and advanced semiconductor packaging materials, has formed a strategic partnership with Merck and Taiwan-based Qualipoly Chemical to offer advanced packaging customers a more complete, faster,... Picks for you